920TiPAfatinib in patients with advanced or metastatic...

920TiPAfatinib in patients with advanced or metastatic urothelial carcinoma (UC) with genetic alterations in ErbB receptors 1–3 who failed on platinum-based chemotherapy: The Phase II LUX-Bladder 1 trial

Font, A., Real, F.X., Puente, J., Vazquez Mazon, F.J., Sala, N., Virizuela, J.A., Rodriguez-Vida, A., Grande Pulido, E., Castellano, D., Climent, M.A., Gallardo, E., González del Alba, A., Fernandez,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
28
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx371.074
Date:
September, 2017
File:
PDF, 81 KB
2017
Conversion to is in progress
Conversion to is failed